Saturday, June 25, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Angiotensin-converting enzyme 2-based mutant decoy effectively reduces COVID-19 in mice

by Medical Finance
in Coronavirus
Study: A decoy mutant ACE2 designed to reduce COVID-19. Image Credit: Kateryna Kon/Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

In a recent study published in the Trends in Pharmacological Sciences, researchers engineered a mutant angiotensin-converting enzyme 2 (ACE2) decoy that effectively protected human lung epithelia from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by competitively binding to its spike (S) protein. Additionally, this mutant decoy improved lung injury in mice expressing human ACE2.

Study: A decoy mutant ACE2 designed to reduce COVID-19. Image Credit: Kateryna Kon/Shutterstock
Study: A decoy mutant ACE2 designed to reduce COVID-19. Image Credit: Kateryna Kon/Shutterstock

There is an urgent need for novel coronavirus disease 2019 (COVID-19) therapies as the SARS-CoV-2 pandemic continues and new variants emerge. Importantly, COVID-19 vaccines are ineffective in preventing breakthrough infection from new SARS-CoV-2 variants, including its new variant of concern (VoC) Omicron.

S protein-ACE2 binding establishes SARS-CoV-2 infection on the host cell surface. Blocking this binding on the surface of cells lining the lung airways, specifically lung alveolar epithelial cells, could effectively prevent SARS-CoV-2 infection.

About the study

In the present study, researchers used deep mutagenesis to develop a mutant ACE2, termed sACE2.v2.4. This mutant ACE2 could bind S protein with a 35-fold higher affinity than wild-type (WT) ACE2 primarily due to its conformational stability.

They tested sACE2.v2.4 in vivo using transgenic mice expressing human ACE2, referred to as K18-hACE2 mice, as they used the epithelial-specific K18 protomer (K18-hACE2). SARS-CoV-2 could enter their lung epithelial cells, injured during COVID-19 infection. Overall, this animal model resembled severe clinical COVID-19, especially concerning lung histology and related features.

The researchers also determined the binding affinity of the decoy sACE22.v2.4-immunoglobulin G1 (IgG1) to S protein. They compared its binding affinity with that of clinically used anti-SARS-CoV-2 antibodies.

Notably, similar to the mutant used in the study, monoclonal antibodies (mAbs) neutralize the virus by binding and preventing its docking and uptake by ACE2 on the cell surface; additionally, they promote virus clearance.

Study findings

Similar engineered ACE2-Fc decoys have successfully contained lung damage and systemic manifestations in hamster models and improved their lung histopathology. Similarly, a study has reported that an ACE2-Fragment, crystallizable(Fc) decoy reduced pulmonary SARS-CoV-2 pseudovirus transduction in K18-hACE2 mice. Due to its Fc component, it had enhanced effector functions that promoted immune clearance of SARS-CoV-2.

The functional analyses relevant to pulmonary microvascular injury in clinical acute respiratory distress syndrome (ARDS) and COVID-19 performed during the study helped researchers investigate mutant ACE2 receptor decoys much more broadly than previous studies. Importantly, in the present study, Zhang et al. also assayed endothelial barrier dysfunction, vascular endothelial (VE)-cadherin integrity, and pulmonary edema formation.

They observed that treatment with sACE22.v2.4-IgG1 decoy restored body-weight of transgenic mice and the overall survival rate; however, it remained unclear whether this treatment reduced injury to lung epithelia. Although after 14 days (rather than seven days) of treatment, edema fluid cleared, and the lung wet/dry ratio normalized, suggesting that the lung epithelium plays a pivotal role in the recovery of mice. These findings are similar to those reported by previous studies on experimental influenza pneumonia.

Majorly due to the IgG1 Fc fragment of the decoy construct intravenous infusion of sACE22.v2.4-IgG1 reduced SARS-CoV-2 loads in the lungs of transgenic mice and enabled immune clearance of free virions and SARS-CoV-2-infected cells.

Although decoy treatment did not have any dramatic effects on the lungs of K18-hACE2 mice; there are some plausible concerns concerning the use of a decoy for treating COVID-19. For instance, they could trigger an autoimmune reaction or aberrant ACE2 activity or interfere with endogenous ACE2 signaling. These possible issues need to be tested in early phase clinical trials.

Multiple previous human clinical trials reports suggest that adverse hemodynamic changes did not occur with WT-soluble ACE2; likewise, ACE2-like enzymatic activity improved SARS-CoV-2-induced lung injury in mice and hamsters.

After inoculating K18-hACE2 mice with the more lethal P.1 variant of SARS-CoV-2, the authors noted that sACE22.v2.4-IgG1 treatment prevented mortality only when administered 12 hours (not 24 hours) post-inoculation, thus recommending an early treatment in case of a lethal variant infection.

Additionally, in vitro, sACE2.v2.4 mutant bound more strongly than WT ACE2 to the S of several SARS-CoV-2 variants. When tested against Omicron, in vitro binding of sACE2.v2.4 to Omicron S was strong, unlike mAbs that failed against Omicron due to its highly mutated S protein.

Conclusion

The sACE2.v2.4 decoy strategy showed promise against SARS-CoV-2-induced lung injury in mice. Even when used against more transmissible and infective SARS-CoV-2 VOCs, the decoy strategy worked remarkably well and the sACE2.v2.4 decoy strongly bound Omicron S.

Together, the study observations suggest that perhaps, the sACE2.v2.4 decoy will remain effective against SARS-CoV-2 variants that are yet to emerge.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Do Some Super-Spreaders Spread Better? Effects of individual heterogeneity in epidemiological traits. Image Credit: Woeywoey/Shutterstock

Characteristics of viral infection super-spreaders

by Medical Finance
June 25, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers evaluated whether certain super-spreaders transmit viral infection better and the...

Study: Peptide derived nanobody inhibits entry of SARS-CoV-2 variants. Image Credit: Lightspring/Shutterstock

Nanobody effectively neutralizes pseudotyped ancestral SARS-CoV-2 and Omicron spike proteins

by Medical Finance
June 25, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers identified a nanobody that inhibits severe acute respiratory syndrome...

Study: Impaired immune response drives age-dependent severity of COVID-19. Image Credit: unoL/Shutterstock

Researchers use mouse model to explore correlation of impaired interferon-mediated immune response with severe COVID-19

by Medical Finance
June 25, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers developed a highly pathogenic mouse-adapted (MA) severe acute respiratory...

Study: A Quantum Dot Biomimetic for SARS-CoV-2 to Interrogate Dysregulation of the Neurovascular Unit Relevant to Brain Inflammation. Image Credit: Yurchanka Siarhei/Shutterstock

Quantum dot biomimetic for SARS-CoV-2 examines neurovascular dysregulation related to brain inflammation

by Medical Finance
June 25, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus-like...

Study: Transcriptomic profiling of cardiac tissues from SARS-CoV-2 patients identifies DNA damage. Image Credit: Jose Luis Calvo/Shutterstock

Study generates a picture of the myocardial transcriptional landscape of COVID-19

by Medical Finance
June 25, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers profiled cardiac tissue transcriptomes of coronavirus disease 2019 (COVID-19)...

Study: Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age. Image Credit: Zouls/Shutterstock

Study explores SARS-CoV-2 antibody responses in mild COVID-19 cases

by Medical Finance
June 25, 2022
0

In a recent study posted to medRxiv* preprint server, researchers evaluated antibody responses in mild cases of coronavirus disease 2019...

Next Post
New tool could help detect geographical hotspots for mental health problems caused by COVID

A health-heavy State of the Union

Study: Variability in transmission risk of SARS-CoV-2 in close contact settings: A contact tracing study in Shandong Province, China. Image Credit: elenabsl/Shutterstock

Contact tracing data from the first COVID-19 pandemic wave in Shandong Province, China

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Image Credit: Orpheus FX / Shutterstock
    Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially
  • Study: High neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination. Image Credit: Firn/Shutterstock
    Booster dose of BNT162b2 mRNA vaccine induces a high cross-neutralizing response against SARS-CoV-2 variants
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply